127 related articles for article (PubMed ID: 10365674)
21. Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan.
Rubello D; Saladini G; Carpi A; Casara D
Biomed Pharmacother; 2000 Jul; 54(6):337-44. PubMed ID: 10989970
[TBL] [Abstract][Full Text] [Related]
22. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.
Ladenson PW; Braverman LE; Mazzaferri EL; Brucker-Davis F; Cooper DS; Garber JR; Wondisford FE; Davies TF; DeGroot LJ; Daniels GH; Ross DS; Weintraub BD
N Engl J Med; 1997 Sep; 337(13):888-96. PubMed ID: 9302303
[TBL] [Abstract][Full Text] [Related]
23. PET in the follow-up of differentiated thyroid cancer.
Khan N; Oriuchi N; Higuchi T; Zhang H; Endo K
Br J Radiol; 2003 Oct; 76(910):690-5. PubMed ID: 14512328
[TBL] [Abstract][Full Text] [Related]
24. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
Unal S; Menda Y; Adalet I; Boztepe H; Ozbey N; Alagöl F; Cantez S
J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579
[TBL] [Abstract][Full Text] [Related]
25. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
26. Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.
Balon HR; Fink-BennetT D; Stoffer SS
J Nucl Med; 1992 Jul; 33(7):1393-5. PubMed ID: 1535374
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic scintigraphy in postoperative staging and follow-up of differentiated thyroid carcinoma.
Casara D; Rubello D
Rays; 2000; 25(2):207-19. PubMed ID: 11370539
[TBL] [Abstract][Full Text] [Related]
28. Technetium-99m tetrofosmin uptake in insular thyroid carcinoma. A comparison with iodine-131.
Degirmenci B; Aydin A; Comlekci A; Ozdogan O; Bekis R
Clin Nucl Med; 2003 May; 28(5):385-8. PubMed ID: 12702934
[TBL] [Abstract][Full Text] [Related]
29. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma.
Alam MS; Takeuchi R; Kasagi K; Misaki T; Miyamoto S; Iida Y; Hidaka A; Konishi J
Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573
[TBL] [Abstract][Full Text] [Related]
30. Conventional gamma and high energy probe for radioguided dissection of metastases in a patient with recurrent thyroid carcinoma with (99m)Tc-MIBI and (18)F-FDG.
Meller B; Sahlmann C; Horstmann O; Gerl J; Baehre M; Meller J
Nuklearmedizin; 2005; 44(3):N23-5. PubMed ID: 15997503
[No Abstract] [Full Text] [Related]
31. [MRI and oncoscintigraphy with 99m-Tc-MIBI in the follow up of thyroid cancer].
Biedermann M; Bares R; Grün B; Dohmen BM; Sabri O; Friedberg C; Büll U
Nuklearmedizin; 1995 Jun; 34(3):87-91. PubMed ID: 7630747
[TBL] [Abstract][Full Text] [Related]
32. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
33. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
[TBL] [Abstract][Full Text] [Related]
34. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions.
Mazzaferri EL; Kloos RT
Thyroid; 2000 Sep; 10(9):767-78. PubMed ID: 11041454
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation.
Alam MS; Kasagi K; Misaki T; Miyamoto S; Iwata M; Iida Y; Konishi J
Thyroid; 1998 Dec; 8(12):1091-100. PubMed ID: 9920363
[TBL] [Abstract][Full Text] [Related]
36. 99mTc-MIBI in differentiated thyroid carcinoma.
Roelants V; Beckers C
J Nucl Med; 1999 Oct; 40(10):1769. PubMed ID: 10520721
[No Abstract] [Full Text] [Related]
37. Molecular imaging in the management of thyroid cancer.
Wong KK; Dvorak RA; Marzola MC; Grassetto G; Gross MD; Rubello D
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):541-59. PubMed ID: 22019711
[TBL] [Abstract][Full Text] [Related]
38. Pre- and post-therapy thallium-201 and technetium-99m-sestamibi SPECT in nasopharyngeal carcinoma.
Kostakoglu L; Uysal U; Ozyar E; Elahi N; Hayran M; Uzal D; Demirkazik FB; Kars A; Uğur O; Atahan L; Bekdik CF
J Nucl Med; 1996 Dec; 37(12):1956-62. PubMed ID: 8970513
[TBL] [Abstract][Full Text] [Related]
39. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
40. Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma--preliminary results.
Gallowitsch HJ; Kresnik E; Mikosch P; Pipam W; Gomez I; Lind P
Nuklearmedizin; 1996 Dec; 35(6):230-5. PubMed ID: 8976503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
